Radiomics on radiography predicts giant cell tumor histologic response to denosumab

Objective Denosumab is an established targeted systemic therapy for treatment of giant cell tumor of bone (GCTB). We sought to determine whether treatment response could be quantified from radiomics analysis of radiographs taken longitudinally during treatment. Materials and methods Pre- and post-tr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Skeletal radiology 2021-09, Vol.50 (9), p.1881-1887
Hauptverfasser: Chang, Yu-Cherng, Stoyanova, Radka, Danilova, Sofia, Pretell-Mazzini, Juan A., Kerr, Darcy A., Wilky, Breelyn A., Subhawong, Ty
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective Denosumab is an established targeted systemic therapy for treatment of giant cell tumor of bone (GCTB). We sought to determine whether treatment response could be quantified from radiomics analysis of radiographs taken longitudinally during treatment. Materials and methods Pre- and post-treatment radiographs of 10 GCTB tumors from 10 patients demonstrating histologic response after treatment with denosumab were analyzed. Intensity- and texture-based radiomics features for each manually segmented tumor were calculated. Radiomics features were compared pre- and post-treatment in tumors. Results Mean intensity ( p  = 0.033) significantly increased while skewness ( p  = 0.028) significantly decreased after treatment. Post-treatment increases in fractal dimensions ( p  = 0.057) and abundance ( p  = 0.065) approached significance. A potential linear correlation in mean ( p  = 0.005; ΔMean = 0.022 * duration − 0.026) with treatment duration was observed. Conclusion Radiomics analysis of plain radiographs quantifies time-dependent matrix mineralization and trabecular reconstitution that mark positive response of giant cell tumors of bone to denosumab.
ISSN:0364-2348
1432-2161
DOI:10.1007/s00256-021-03752-5